ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Automated Monitoring of Four Urinary Biomarkers in Routine Surveillance Identifies Patients at Low and High Risk of Renal Allograft Injury

L. Sheward1, J. Wedel1, N. Rodig1, R. Mannon2, O. Bestard3, V. Dharnidharka4, D. Zurakowski1, A. Kho1, T. Blydt-Hansen5, M. Seifert2, D. M. Briscoe1

1Boston Children's Hospital, Boston, MA, 2University of Alabama at Birmingham, Birmingham, AL, 3Bellvitge University Hospital, Barcelona, Spain, 4St Louis Children's Hospital, St Louis, MO, 5BC Children's Hospital, Vancouver, BC, Canada

Meeting: 2020 American Transplant Congress

Abstract number: 308

Keywords: Kidney transplantation, Multicenter studies, Pediatric, Rejection

Session Information

Session Name: Biomarkers, Immune Assessment and Clinical Outcomes III

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:39pm-3:51pm

Location: Virtual

*Purpose: Surveillance renal biopsy data indicate that up to 36% of clinically stable kidney allograft recipients have subclinical rejection, emphasizing the need to implement automated and sensitive technology to bring biomarkers into clinical practice. In this study, we used a novel platform to measure established urine biomarkers (CXCL9, CXCL10, CCL2 and VEGFA) simultaneously with a high level of precision, and test the hypothesis that patterns of expression serve as a new gold standard to identify stable patients post transplant.

*Methods: We collected urine from a total of 515 adult and pediatric renal allograft recipients who underwent surveillance or indication biopsy at four sites. Biomarkers were measured on the SimplePlex platform (ProteinSimple Inc.), and levels were compared in patients with normal, borderline or acute rejection by histology. Principal component (PC) analysis, non-parametric rank analysis and ROC curve analyses were used to analyze biomarker performance.

*Results: Of the 515 test samples, biopsy histology was reported as normal (n=320), acute rejection (n=102) and borderline rejection (n=92). Unsupervised PC analysis of all 4 biomarkers revealed heterogeneity among each diagnostic group (PC1=75%), which was attributed to changes in CCL2 and CXCL10. Moreover, there was clustering of normal and borderline diagnoses while the greatest degree of heterogeneity was within patients with acute rejection. Using the rank sum test, we found that each biomarker independently discriminated normal vs. acute rejection (P<0.00001), whereas only CCL2 trended higher in patients with borderline rejection (P=0.03). Of all biomarkers, CXCL9 and CXCL10 provide the best diagnostic performance for the diagnosis of acute rejection (AUC 0.79 and 0.84, respectively). Based on a Bayes analysis and assuming a 20% incidence of acute rejection, the negative predictive value of CXCL10 was 88%. To evaluate the significance of our findings, we subsequently tested 79 samples in an additional cohort of clinically stable patients and identified 67% as stable vs. 33% with concern for subclinical disease using biomarker assays alone.

*Conclusions: This study represents one of the largest cohort analyses of multianalyte urinary biomarker profiling following renal transplantation. It suggests that automated monitoring of urinary biomarkers accurately classifies stable patients vs. those with active intragraft inflammation. Sensitive multianalyte assays have potential to outperform surveillance biopsy for the monitoring of at-risk patients and may serve as a precision tool to identify eligibility for minimization or pro-tolerogenic regimens.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Sheward L, Wedel J, Rodig N, Mannon R, Bestard O, Dharnidharka V, Zurakowski D, Kho A, Blydt-Hansen T, Seifert M, Briscoe DM. Automated Monitoring of Four Urinary Biomarkers in Routine Surveillance Identifies Patients at Low and High Risk of Renal Allograft Injury [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/automated-monitoring-of-four-urinary-biomarkers-in-routine-surveillance-identifies-patients-at-low-and-high-risk-of-renal-allograft-injury/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences